"And finally, a good update on Herceptin subcu. We launched in now 18 countries. We have some countries with shares up to around 30% to 40% already. I think it speaks to the value that this brings to healthcare systems and again part of our overall strategy to grow the HER2 franchise over time. Because if you remember Herceptin subcu would also have some additional patent life to extend it, and this really provides significant advances to the clinics and hospitals in terms of their workflow and patient advantages, as we’ve seen from the studies we’ve done there that we think are quite sustainable."
"And now on slide 21, as you know, we’ve got the approval in the first quarter for MabThera subcutaneous and we’ll begin rolling that out in European countries over the next several months"
from seekingalpha
News 
Market Data 
Discover 
